113
Views
7
CrossRef citations to date
0
Altmetric
Review

Current status of probiotics for prevention and management of gastrointestinal cancers

, &
Pages 413-422 | Received 13 Jul 2020, Accepted 23 Sep 2020, Published online: 09 Oct 2020

References

  • Pourhoseingholi MA, Vahedi M, Baghestani AR. Burden of gastrointestinal cancer in Asia; an overview. Gastroenterol Hepatol Bed Bench. 2015 Winter;8(1):19–27.
  • Somi MH, Dolatkhah R, Sepahi S, et al. A 12-year trend analysis of the incidence of gastrointestinal cancers in East Azerbaijan: last updated results of an ongoing population-based cancer registry. BMC Cancer. 2019 Aug 7;19(1):782.
  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
  • Serban DE. Gastrointestinal cancers: influence of gut microbiota, probiotics and prebiotics. Cancer Lett. 2014 Apr 10;345(2):258–270.
  • Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, et al. Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. Acta Oncologica. 2018;57(2):195–202. 2018/02/01.
  • Ogino S, Nishihara R, VanderWeele TJ, et al. Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology. 2016 Jul;27(4):602–611.
  • Banks M, Graham D, Jansen M, et al. British society of gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68(9):1545.
  • Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) consortium. Gut. 2020 Jan;69(1):7–17.
  • Kuipers EJ, Spaander MC. Personalized screening for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol. 2018 Jul;15(7):391–392.
  • Dizdar Ö, Kılıçkap S. Global epidemiology of gastrointestinal cancers. In: Yalcin S, Philip PA, editors. Textbook of gastrointestinal oncology. Cham: Springer International Publishing; 2019. p. 1–12.
  • Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016 Aug;14(8):e1002533.
  • Vuik FER, Dicksved J, Lam SY, et al. Composition of the mucosa-associated microbiota along the entire gastrointestinal tract of human individuals. United European Gastroenterol J. 2019;7(7):897–907. 2019/08/01.
  • Lam SY, Yu J, Wong SH, et al. The gastrointestinal microbiota and its role in oncogenesis. Best Pract Res Clin Gastroenterol. 2017 Dec;31(6):607–618.
  • Rugge M, Genta RM, Di Mario F, et al. Gastric cancer as preventable disease. Clin Gastroenterol Hepatol. 2017 Dec;15(12):1833–1843.
  • Li S, Fuhler GM, Bn N, et al. Pancreatic cyst fluid harbors a unique microbiome. Microbiome. 2017;5(1):147. 2017/11/09.
  • Khan AA, Shrivastava A, Khurshid M. Normal to cancer microbiome transformation and its implication in cancer diagnosis. Biochim Biophys Acta. 2012 Dec;1826(2):331–337.
  • Grobbee EJ, Lam SY, Fuhler GM, et al. First steps towards combining faecal immunochemical testing with the gut microbiome in colorectal cancer screening. United European Gastroenterol J. 2020 Apr;8(3):293–302.
  • Nagpal R, Kumar A, Kumar M, et al. Probiotics, their health benefits and applications for developing healthier foods: a review. FEMS Microbiol Lett. 2012 Sep;334(1):1–15.
  • Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nature Rev Microbiol. 2005 Oct;3(10):777–788.
  • Javanmard A, Ashtari S, Sabet B, et al. Probiotics and their role in gastrointestinal cancers prevention and treatment; an overview. Gastroenterol Hepatol Bed Bench. 2018 Fall;11(4):284–295.
  • Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev. 2004 Oct;28(4):405–440.
  • Kostic AD, Chun E, Meyerson M, et al. Microbes and inflammation in colorectal cancer. Cancer Immunol Res. 2013 Sep;1(3):150–157.
  • Uronis JM, Jobin C. Microbes and colorectal cancer: is there a relationship? Current Oncol. 2009 Aug;16(4):22–24.
  • Holzapfel WH, Haberer P, Geisen R, et al. Taxonomy and important features of probiotic microorganisms in food and nutrition. Am J Clin Nutr. 2001 Feb;73(2Suppl):365S–373S.
  • Nissle A. [Explanations of the significance of colonic dysbacteria & the mechanism of action of E. coli therapy (mutaflor)]. Die Medizinische. 1959 May 23;4(21):1017–1022.
  • Mollenbrink M, Bruckschen E. [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)]. Medizinische Klinik. 1994 Nov 15;89(11):587–593.
  • Schutz E. [The treatment of intestinal diseases with Mutaflor. A multicenter retrospective study]. Fortschritte der Medizin. 1989 Sep 30;107(28):599–602.
  • Salminen S, Bouley C, Boutron-Ruault MC, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr. 1998 Aug;80(Suppl 1):S147–71.
  • Tuomola E, Crittenden R, Playne M, et al. Quality assurance criteria for probiotic bacteria. Am J Clin Nutr. 2001 Feb;73(2Suppl):393S–398S.
  • Di Cerbo A, Palmieri B. Review: the market of probiotics. Pak J Pharm Sci. 2015 Nov;28(6):2199–2206.
  • Orlando A, Russo F. Intestinal microbiota, probiotics and human gastrointestinal cancers. J Gastrointest Cancer. 2013 Jun;44(2):121–131.
  • Casey SC, Vaccari M, Al-Mulla F, et al. The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis. 2015 Jun;36(Suppl 1):S160–83.
  • Khan AA, Khan Z, Malik A, et al. Colorectal cancer-inflammatory bowel disease nexus and felony of Escherichia coli. Life Sci. 2017 Jul;1(180):60–67.
  • Stein CJ, Colditz GA. Modifiable risk factors for cancer. Br J Cancer. 2004 Jan 26;90(2):299–303.
  • Pomerantz MM, Freedman ML. The genetics of cancer risk. Cancer J. 2011 Nov-Dec;17(6):416–422.
  • Testa U, Pelosi E, Castelli G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med Sci. 2018 Apr 13;6:2.
  • Choi YJ, Kim N. Gastric cancer and family history. Korean J Intern Med. 2016 Nov;31(6):1042–1053.
  • Karl JP, Hatch AM, Arcidiacono SM, et al. Effects of psychological, environmental and physical stressors on the gut microbiota. Front Microbiol. 2018;9:2013.
  • Hamada T, Keum N, Nishihara R, et al. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol. 2017 Mar;52(3):265–275.
  • Ogino S, Nowak JA, Hamada T, et al. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu Rev Pathol. 2019 Jan;24(14):83–103.
  • Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PloS One. 2012;7(4):e34938.
  • Kumar M, Kumar A, Nagpal R, et al. Cancer-preventing attributes of probiotics: an update. Int J Food Sci Nutr. 2010 Aug;61(5):473–496.
  • Nowak A, Paliwoda A, Blasiak J. Anti-proliferative, pro-apoptotic and anti-oxidative activity of Lactobacillus and Bifidobacterium strains: A review of mechanisms and therapeutic perspectives. Crit Rev Food Sci Nutr. 2019;59(21):3456–3467.
  • Lee JW, Shin JG, Kim EH, et al. Immunomodulatory and antitumor effects in vivo by the cytoplasmic fraction of Lactobacillus casei and Bifidobacterium longum. J Vet Sci. 2004 Mar;5(1):41–48.
  • Baldwin C, Millette M, Oth D, et al. Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. Nutr Cancer. 2010;62(3):371–378.
  • Russo F, Orlando A, Linsalata M, et al. Effects of Lactobacillus rhamnosus GG on the cell growth and polyamine metabolism in HGC-27 human gastric cancer cells. Nutr Cancer. 2007;59(1):106–114.
  • Orlando A, Messa C, Linsalata M, et al. Effects of Lactobacillus rhamnosus GG on proliferation and polyamine metabolism in HGC-27 human gastric and DLD-1 colonic cancer cell lines. Immunopharmacol Immunotoxicol. 2009;31(1):108–116.
  • Kim Y, Lee D, Kim D, et al. Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium adolescentis SPM0212. Arch Pharm Res. 2008 Apr;31(4):468–473.
  • Ma EL, Choi YJ, Choi J, et al. The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. Int J Cancer. 2010 Aug 15;127(4):780–790.
  • Tukenmez U, Aktas B, Aslim B, et al. The relationship between the structural characteristics of lactobacilli-EPS and its ability to induce apoptosis in colon cancer cells in vitro. Sci Rep. 2019 Jun 4;9(1):8268.
  • Stein K, Borowicki A, Scharlau D, et al. Effects of synbiotic fermentation products on primary chemoprevention in human colon cells. J Nutr Biochem. 2012 Jul;23(7):777–784.
  • Cousin FJ, Jouan-Lanhouet S, Dimanche-Boitrel MT, et al. Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells. PloS One. 2012;7(3):e31892.
  • Ranji P, Agah S, Heydari Z, et al. Effects of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics on the serum biochemical parameters, and the vitamin D and leptin receptor genes on mice colon cancer. Iran J Basic Med Sci. 2019 Jun;22(6):631–636.
  • Zaharuddin L, Mokhtar NM, Muhammad Nawawi KN, et al. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol. 2019 Jul 24;19(1):131.
  • Liu D, Jiang XY, Zhou LS, et al. Effects of probiotics on intestinal mucosa barrier in patients with colorectal cancer after operation: meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016 Apr;95(15):e3342.
  • Kotzampassi K, Stavrou G, Damoraki G, et al. A four-probiotics regimen reduces postoperative complications after colorectal surgery: a randomized, double-blind, placebo-controlled study. World J Surg. 2015 Nov;39(11):2776–2783.
  • Aisu N, Tanimura S, Yamashita Y, et al. Impact of perioperative probiotic treatment for surgical site infections in patients with colorectal cancer. Exp Ther Med. 2015 Sep;10(3):966–972.
  • Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014 Sep;40(5):409–421.
  • Thomsen M, Vitetta L. Adjunctive treatments for the prevention of chemotherapy- and radiotherapy-induced mucositis. Integr Cancer Ther. 2018 Dec;17(4):1027–1047.
  • Molska M, Regula J. Potential mechanisms of probiotics action in the prevention and treatment of colorectal cancer. Nutrients. 2019 14;11(10):Oct.
  • Park JY, Forman D, Waskito LA, et al. Epidemiology of helicobacter pylori and cagA-positive infections and global variations in gastric cancer. Toxins (Basel). 2018 Apr 19;10(4):163.
  • Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol. 2015 Oct 7;21(37):10644–10653.
  • Zhu XY, Liu F. Probiotics as an adjuvant treatment in Helicobacter pylori eradication therapy. J Dig Dis. 2017 Apr;18(4):195–202.
  • Fu GF, Li X, Hou YY, et al. Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther. 2005 Feb;12(2):133–140.
  • Lahtinen SJ, Haskard CA, Ouwehand AC, et al. Binding of aflatoxin B1 to cell wall components of Lactobacillus rhamnosus strain GG. Food Addit Contam. 2004 Feb;21(2):158–164.
  • Haskard C, Binnion C, Ahokas J. Factors affecting the sequestration of aflatoxin by Lactobacillus rhamnosus strain GG. Chem Biol Interact. 2000 Aug 15;128(1):39–49.
  • Olah A, Belagyi T, Poto L, et al. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepato-gastroenterology. 2007 Mar;54(74):590–594.
  • Olah A, Belagyi T, Issekutz A, et al. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg. 2002 Sep;89(9):1103–1107.
  • Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Feb 23;371(9613):651–659.
  • Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Clin Pract Gastroenterol Hepatol. 2018 Jul;15(7):397–411.
  • De Minicis S, Rychlicki C, Agostinelli L, et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014 May;59(5):1738–1749.
  • Wong VW, Tse CH, Lam TT, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis–a longitudinal study. PloS One. 2013;8(4):e62885.
  • Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013 Jul 4;499(7456):97–101.
  • Khan AA, Khurshid M, Khan S, et al. Gut Microbiota and Probiotics: current Status and Their Role in Cancer Therapeutics. Drug Dev Res. 2013;74(6):365–375.
  • LeBlanc JG, de LeBlanc A. Chapter 57 - probiotics in inflammatory bowel diseases and cancer prevention. In: Watson RR, Preedy VR, editors. Probiotics, prebiotics, and synbiotics - Bioactive Foods in Health Promotion. USA: Academic Press; 2016. p. 755–771.
  • Altonsy MO, Andrews SC, Tuohy KM. Differential induction of apoptosis in human colonic carcinoma cells (Caco-2) by Atopobium, and commensal, probiotic and enteropathogenic bacteria: mediation by the mitochondrial pathway. Int J Food Microbiol. 2010 Feb 28;137(2–3):190–203.
  • Jan G, Belzacq AS, Haouzi D, et al. Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. Cell Death Differ. 2002 Feb;9(2):179–188.
  • Kim Y, Oh S, Yun HS, et al. Cell-bound exopolysaccharide from probiotic bacteria induces autophagic cell death of tumour cells. Lett Appl Microbiol. 2010 Aug;51(2):123–130.
  • LeBlanc JG, Matar C, Valdéz JC, et al. Immunomodulating effects of peptidic fractions issued from milk fermented with lactobacillus helveticus. J Dairy Sci. 2002;85(11):2733–2742. 2002/11/01/.
  • LeBlanc JG, Levit R, Savoy de Giori G, et al. Application of vitamin-producing lactic acid bacteria to treat intestinal inflammatory diseases. Appl Microbiol Biotechnol. 2020;104(8):3331–3337. 2020/04/01.
  • Takagi A, Matsuzaki T, Sato M, et al. Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Carcinogenesis. 2001 Apr;22(4):599–605.
  • Drago L. Probiotics and colon cancer. Microorganisms. 2019 Feb 28;7(3):66.
  • O’Mahony L, Feeney M, O’Halloran S, et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther. 2001 Aug;15(8):1219–1225.
  • Lenoir M, Del Carmen S, Cortes-Perez NG, et al. Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer. J Gastroenterol. 2016 Sep;51(9):862–873.
  • Gratz S, Taubel M, Juvonen RO, et al. Lactobacillus rhamnosus strain GG modulates intestinal absorption, fecal excretion, and toxicity of aflatoxin B(1) in rats. Appl Environ Microbiol. 2006 Nov;72(11):7398–7400.
  • Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr. 2000 Feb;130(2SSuppl):396S–402S.
  • Del Carmen S, de Moreno de LeBlanc A, LeBlanc JG. Development of a potential probiotic yoghurt using selected anti-inflammatory lactic acid bacteria for prevention of colitis and carcinogenesis in mice. J Appl Microbiol. 2016;121(3):821–830.
  • de LeBlanc A, Bibas Bonet ME, LeBlanc JG, et al. Chapter 29 - Probiotics in Cancer Prevention. In: Watson RR, Preedy VR, editors. Bioactive Foods in Promoting Health. Boston: Academic Press; 2010. p. 497–511.
  • Levit R, de Giori GS, de LeBlanc A, et al. Chapter 15 - increasing B vitamins in foods to prevent intestinal inflammation and cancer. In: Watson RR, Collier RJ, Preedy VR, editors. Nutrients in dairy and their implications on health and disease. USA: Academic Press; 2017. p. 193–204.
  • de Moreno de LeBlanc A, LeBlanc JG. Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications. World J Gastroenterol. 2014 Nov 28;20(44):16518–16528.
  • Ma B, Pan Q, Peppelenbosch MP. Genetically engineered bacteria for treating human disease. Trends Pharmacol Sci. 2017;38(9):763–764. 2017/09/01/.
  • Del Carmen S, de Moreno de LeBlanc A, Levit R, et al. Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model. Int Immunopharmacol. 2017;42:122–129.
  • Khan AA, Cash P. E. coli and colon cancer: is mutY a culprit? Cancer Lett. 2013;341(2):127–131. 2013/12/01/.
  • Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature. 2020;580(7802):269–273. 2020/04/01.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.